NASDAQ:PALI

Palisade Bio Q2 2025 Earnings Results & Report

Palisade Bio logo
$0.84 -0.09 (-9.24%)
Closing price 04:00 PM Eastern
Extended Trading
$0.86 +0.02 (+2.39%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palisade Bio missed analyst earnings expectations in its Q2 2025 results, released August 11, 2025. The company reported EPS of -$0.58 versus the -$0.48 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Palisade Bio EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Palisade Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Palisade Bio Q2 2025 Earnings FAQ

Palisade Bio (NASDAQ:PALI) reported earnings of -$0.58 per share for Q2 2025, missing the consensus estimate of -$0.48. The report was announced on Monday, August 11, 2025.

Palisade Bio Earnings Headlines

FY2026 EPS Estimate for Palisade Bio Reduced by Analyst
FY2026 EPS Forecast for Palisade Bio Reduced by Analyst
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Palisade Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email.

About Palisade Bio

Palisade Bio (NASDAQ:PALI) is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions.

Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

Palisade Bio’s candidates are in clinical development and are not approved for commercial use.

View Palisade Bio Profile